Free Trial
NASDAQ:MAZE

Maze Therapeutics (MAZE) Stock Price, News & Analysis

Maze Therapeutics logo
$15.32 +0.83 (+5.73%)
As of 09/2/2025 04:00 PM Eastern

About Maze Therapeutics Stock (NASDAQ:MAZE)

Key Stats

Today's Range
$14.44
$15.60
50-Day Range
$11.41
$17.78
52-Week Range
$6.71
$19.19
Volume
513,675 shs
Average Volume
275,935 shs
Market Capitalization
$671.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.33
Consensus Rating
Buy

Company Overview

Receive MAZE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MAZE Stock News Headlines

Maze Therapeutics Names Misbah Tahir Chief Financial Officer
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
Maze Therapeutics Appoints Misbah Tahir as CFO
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
See More Headlines

MAZE Stock Analysis - Frequently Asked Questions

Maze Therapeutics' stock was trading at $13.38 at the beginning of the year. Since then, MAZE stock has increased by 14.5% and is now trading at $15.32.

Maze Therapeutics, Inc. (NASDAQ:MAZE) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Maze Therapeutics (MAZE) raised $140 million in an IPO on Friday, January 31st 2025. The company issued 8,750,000 shares at a price of $16.00 per share.

Maze Therapeutics's lock-up period expired on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its IPO on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Maze Therapeutics' top institutional investors include Frazier Life Sciences Management L.P. (10.42%), Geode Capital Management LLC (0.53%), Octagon Capital Advisors LP (0.41%) and Boothbay Fund Management LLC (0.17%).

Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
9/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MAZE
Previous Symbol
NASDAQ:MAZE
CIK
1842295
Web
N/A
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

High Price Target
$34.00
Low Price Target
$17.00
Potential Upside/Downside
+71.9%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.63
Quick Ratio
13.63

Sales & Book Value

Annual Sales
$167.50 million
Price / Sales
4.01
Cash Flow
$0.16 per share
Price / Cash Flow
94.65
Book Value
$5.98 per share
Price / Book
2.56

Miscellaneous

Outstanding Shares
43,850,000
Free Float
N/A
Market Cap
$671.78 million
Optionable
N/A
Beta
N/A

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:MAZE) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners